A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients

Clinical Nephrology

Volumn 59, Issue 5, 2003, Pages 319-325

  Mazess, R B ^a   Elangovan, L ^b  

^a Bone Care International   (United States)

^b NONE

Author keywords

Calcitriol; Dialysis; Renal failure; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; DOXERCALCIFEROL; PARATHYROID HORMONE; VITAMIN D DERIVATIVE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS PATIENT; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; PARATHYROID HORMONE BLOOD LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 0038395930     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP59319     Document Type: Review

References (45)

1. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ 1989 Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-279
2. Andress DL 2001 Intravenous versus oral vitamin D therapy in dialysis patients: what is the question? Am J Kidney Dis 38 (Suppl 5): S41-S44
3. Ardissino G, Schmitt CP, Bianchi ML, Dacco V, Claris-Appiani A, Mehls O 2000 No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. Kidney Int 58: 981-988
4. Bacchini G, Fabrizi F, Pontoriero G, Marcelli D, Di Filippo S, Locatelli F 1997 "Pulse oral" versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study. Nephron 77: 267-272
5. 3 bolus in normal subjects. J Bone Miner Res 14: 1789-1795
6. 3 treatment of secondary hyperparathyroidism in uremia. J Intern Med 239: 353-360
7. Brown AJ, Slatopolsky E 1999 Vitamin D analogs: perspectives for treatment. Miner Electrolyte Metab 25: 337-341
8. Caravaca F, Cubero JJ, Jimenez F, Lopez JM, Aparicio A, Cid MC, Pizarro JL, Liso J, Santos I 1995 Effect of the mode of calcitriol administration on PTH-ionized calcium relationship in uremic patients with secondary hyperparathyroidism. Nephrol Dial Transplant 10: 665-670
9. Coburn JW 1990 Use of an oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 38 (Suppl 29): S34-S61
10. 3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis. Am J Nephrol 17: 505-510
11. Faugere M-C, Friedler RM, Malluche HH 1993 Efficacy and limitations of pulse i.v. and pulse oral 1,25 vit D therapy on bone disease in patients on chronic dialysis (abstract). J Am Soc Nephrol 4: 695
12. Fischer ER, Harris DC 1993 Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 40: 216-220
13. Fockens P, Hillen PH, van Boven WPL, van Buchem-Ramakers Th, Juttmann JR 1986 Suppressive effects of vitamin D on hyperparathyroidism in uremia: oral or intravenous? Presented at the 9th International Conference on Calcium Regulating Hormone, Nice, France
14. 3 derivatives in the treatment of renal bone disease: justification and optimal modalities of administration. Nephron 71: 254-283
15. Gadallah MF, Arora N, Torres C, Ramdeen G, Schaeffer-Pautz A, Moles K 2000 Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients. Adv Perit Dial 16: 303-307
16. Gonzalez E, Bander S, Thielan B, Martin KJ 1991 Comparison of intravenous and pulse oral calcitriol for suppression of PTH in patients on hemodialysis. J Am Soc Nephrol 2: 636
17. Herrmann P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Nonnast-Daniel B, Koch KM, Weber U, Horl W, Haas-Worle A et al 1994 Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 67: 48-53
18. Indridason OS, Quarles LD 2000 Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 57: 282-292
19. Joffe P, Cintin C, Ladefoged SD, Rasmussen SN 1994 Pharmacokinetics of 1-alpha-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. Clin Nephrol 41: 364-369
20. Johnson CA, Storer B 2001 Analysis of a large provider database to compare clinical experiences with calcitriol and paricalcitol (Abstract A4004). J Am Soc Nephrol 12: 766A
21. 3 therapy in children treated with peritoneal dialysis. Clin Nephrol 42: 44-49
22. 3 in patients on chronic hemodialysis. Clin Nephrol 35: 72-77
23. Kiss D, Kraenzlin M 1994 Comparison of pulse intravenous (i.v.) versus oral (p.o.) calcitriol treatment of secondary hyperparathyroidism (HPT) in chronic hemodialysis patients (HD PTS) (abstract). J Am Soc Nephrol 5: 883
24. Lee WT, Padayachi K, Collins JF, Cundy T 1994 A comparison of oral and intravenous alpha-calcidol in the treatment of uremic hyperparathyroidism. J Am Soc Nephrol 5: 1344-1348
25. Levine BS, Song M 1996 Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 7: 488-496
26. Lion HH, Chiang SS, Huang TP, Shieh SD, Akmal M 1994 Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 20: 97-102
27. Maung HM, Elangovan L, Frazao JM, Bower JD, Kelley BJ, Acchiardo SR, Rodriguez HJ, Norris KC, Sigala JF, Rutkowski M, Robertson JA, Goodman WG, Levine BS, Chesney RW, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW 2001 Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1-alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 37: 532-543
28. Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Di Sanza P, Sardella D, Taggi F, Coen G 1994 Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study. Miner Electrolyte Metab 20: 122-129
29. Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M 1998 Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 13: 1234-1241
30. Monier-Faugere MC, Malluche HH 1994 Calcitriol pulse therapy in patients with end-stage renal failure. Curr Opin Nephrol Hypertens 3: 615-619
31. Norris KC, Kraut JA, Andress DL, Agre KL, Sherrard DJ, Coburn JW 1986 Intravenous calcitriol: effects in severe secondary hyperparathyroidism. J Bone Miner Res 1 (Suppl 1): 374
32. Oettinger CW, Oliver JC, Macon EJ 1992 The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients. J Am Soc Nephrol 3: 995-1001
33. Peng SJ, Yang CS, Ferng SH, Chen LY 1997 A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients. Miner Electrolyte Metab 23: 13-18
34. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA 1994 Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45: 1710-1721
35. Quarles LD, Indridason OS 1996 Calcitriol administration in end-stage renal disease: intravenous or oral? Pediatr Nephrol 10: 331-336
36. Rosenkranz AR, Thalhammer F, Holub, Novacek G, Traindl O 1994 Calcitriol - daily oral or intravenous pulse therapy (abstract). J Am Soc Nephrol 5: 887
37. Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC, Adams JS, Holloway M, Fine RN, Coburn JW 1990 Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 16: 126-132
38. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, Goodman WG 1998 Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54: 907-914
39. Schroeder NJ, Cunningham J 2000 What's new in vitamin D for the nephrologist? Nephrol Dial Transplant 15: 460-466
40. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ 1984 Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-2143
41. Slatopolsky E, Brown AJ 1997 Vitamin D and its analogs in chronic renal failure. Osteoporos Int 7 (Suppl 3): S202-S208
42. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL 1999 A phase I trial of calcitriol (1,25-dihydrocholecalciferol) in patients with advanced malignancy. Clin Cancer Res 5: 1339-1345
43. Steddon SJ, Schroeder NJ, Cunningham J 2001 Vitamin D analogues: how do they differ and what is their clinical role? Nephrol Dial Transplant 16: 1965-1967
44. Susanna F, Borsato N, Rossi B, Minello S, Ferlin G, Cascone C 1995 Treatment of secondary hyperparathyroidism with low dose intermittent calcitriol in hemodialysis patients. Imaging and cost analysis. ASAIO J 41: M688-M693
45. Talbot JR, Hammond P, Farley SM, Baylink DJ, Kraenzlin M, Pandian M, Cutler R 1999 Intravenous but not oral 1,25D therapy in renal failure patients increases biochemical markers of bone formation. Osteology 2: 51-57